AB‐MDMSBA—Not a Synthetic Cannabinoid Receptor Agonist
Abstract Synthetic cannabinoids remain one of the most prominent classes of New Psychoactive Substances (NPS). The introduction of “blanket bans”…
Synthetic cannabinoid receptor agonist
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor
Abstract The rapid structural evolution and emergence of novel synthetic cannabinoid receptor agonists (SCRAs) in the recreational market remains a…
Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite
Abstract Purpose: AMB-FUBINACA is a synthetic cannabinoid receptor agonist (SCRA) which is primarily metabolised by hepatic enzymes producing AMB-FUBINACA carboxylic…
Adolescent self-administration of the synthetic cannabinoid receptor agonist JWH-018 induces neurobiological and behavioral alterations in adult male mice
Abstract Rationale: The use of synthetic cannabinoid receptor agonists (SCRAs) is growing among adolescents, posing major medical and psychiatric risks.…
Simultaneous fatal poisoning of two victims with 4F-MDMB-BINACA and ethanol
Abstract Purpose: Methyl-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (4F-MDMB-BINACA) is a newly emerging synthetic cannabinoid receptor agonists (SCRA) first described in 2018 in both Europe…
The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
Abstract Introduction: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups,…
Differential activation of G protein‐mediated signaling by synthetic cannabinoid receptor agonists
Abstract Synthetic cannabinoid receptor agonists (SCRAs) are new psychoactive substances associated with acute intoxication and even death. However, the molecular…